Abstract
Emergence of variant type of Creutzfeldt-Jakob disease (vCJD) in humans due to infection from bovine spongiform encephalopathy contaminated beef and recent reports of human-to-human transmission of vCJD via blood transfusion have raised great concern about an epidemic of vCJD. The disease is currently difficult to diagnose during preclinical stages and requires a very long incubation period for neurological symptoms to be evident. This therefore suggests that the disease is already latently spreading and that opportunity for infection is thus growing among human populations. Interestingly, passive immunization with antibodies against prion protein (PrP), a major component of the prion infectious agents, was shown to protect mice from infection, indicating the possibility of prion vaccines. However, PrP is a host protein therefore immune tolerance to PrP has hampered development of them. Here, the so far reported attempts to overcome the tolerance to elicit protective immunity to prions are briefly reviewed.
Keywords: Vaccine, prion, prion protein, prion disease, immune tolerance
Protein & Peptide Letters
Title: Prospects for Preventative Vaccines Against Prion Diseases
Volume: 16 Issue: 3
Author(s): Suehiro Sakaguchi
Affiliation:
Keywords: Vaccine, prion, prion protein, prion disease, immune tolerance
Abstract: Emergence of variant type of Creutzfeldt-Jakob disease (vCJD) in humans due to infection from bovine spongiform encephalopathy contaminated beef and recent reports of human-to-human transmission of vCJD via blood transfusion have raised great concern about an epidemic of vCJD. The disease is currently difficult to diagnose during preclinical stages and requires a very long incubation period for neurological symptoms to be evident. This therefore suggests that the disease is already latently spreading and that opportunity for infection is thus growing among human populations. Interestingly, passive immunization with antibodies against prion protein (PrP), a major component of the prion infectious agents, was shown to protect mice from infection, indicating the possibility of prion vaccines. However, PrP is a host protein therefore immune tolerance to PrP has hampered development of them. Here, the so far reported attempts to overcome the tolerance to elicit protective immunity to prions are briefly reviewed.
Export Options
About this article
Cite this article as:
Sakaguchi Suehiro, Prospects for Preventative Vaccines Against Prion Diseases, Protein & Peptide Letters 2009; 16 (3) . https://dx.doi.org/10.2174/092986609787601804
DOI https://dx.doi.org/10.2174/092986609787601804 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors
Current Topics in Medicinal Chemistry miRNA Regulation of Glutathione Homeostasis in Cancer Initiation, Progression and Therapy Resistance
MicroRNA Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Cisplatin Resistance and Transcription Factors
Current Medicinal Chemistry - Anti-Cancer Agents Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Anti-Cancer Cytotoxic Effects of Multiwalled Carbon Nanotubes
Current Pharmaceutical Design Grape Seed Proanthocyanidins Protect N2a Cells against Ischemic Injury via Endoplasmic Reticulum Stress and Mitochondrial-associated Pathways
CNS & Neurological Disorders - Drug Targets Phenothiazines and Related Drugs as Multi Drug Resistance Reversal Agents in Cancer Chemotherapy Mediated by p-glycoprotein
Current Cancer Therapy Reviews The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease
Current Drug Safety Unmasking the Many Faces of Giloy (<i>Tinospora cordifolia</i> L.): A Fresh Look on its Phytochemical and Medicinal Properties
Current Pharmaceutical Design Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry